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Abstract 
Inflammation contributes to the development and progression of cancer. 
Interleukin-17 (IL-17) is an inflammatory cytokine that functions in inflammation 
and cancer, as well as several other cellular processes. In this study, we 
investigated the roles and the prognostic value of IL-17 and the IL-17 receptor 
(IL-17R) in lung cancer. Gene expression microarray analysis followed by 
Kaplan-Meier survival curve showed that IL-17B was associated with poor 
patient survival, and IL-17B receptor (IL-17RB) was up-regulated in lung 
cancer tissue compared with normal tissue. Expression of IL-17RB was 
associated with lymph node metastasis and distant metastasis, as well as poor 
patient survival. IL-17RB overexpression significantly increased cancer cell 
invasion/migration and metastasis in vitro and in vivo. IL-17RB induced ERK 
phosphorylation, resulting in GSK3β inactivation and leading to β-catenin 
up-regulation. IL-17RB also participated in IL-17B synthesis via the ERK 
pathway. IL-17RB activation is required for IL-17B-mediated ERK 
phosphorylation. Taken together, IL-17B-IL-17RB signaling and ERK 
participate in a positive feedback loop that enhances invasion/migration ability 
in lung cancer cell lines. IL-17RB may therefore serve as an independent 
prognostic factor and a therapeutic target for lung cancer. 
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Introduction 
Lung cancer is associated with high mortality worldwide, and more than 
80% of lung cancer cases are non-small cell lung cancers (NSCLCs) [15, 35]. 
Therefore, it is critical for researchers to identify prognostic factors and 
therapeutic targets for lung cancer. Accumulating evidence shows that a 
strong association exists between chronic inflammation and tumorigenesis in 
different types of cancers, including lung cancer [2, 7, 10]. Moreover, lung 
diseases, including chronic obstructive pulmonary disease (COPD), idiopathic 
pulmonary fibrosis, tobacco smoke, air pollutants, pulmonary infections and 
occupational dust, are all associated with lung cancer, suggesting chronic 
inflammation plays an important role in the pathogenesis of lung cancer [7, 10, 
27, 28]. 
The interleukin receptor family is distinct from other 
single-transmembrane domain protein families and, upon interleukin binding,  
functions in multiple cellular processes, including inflammation, immunity and 
cancer [24]. In particular, the interleukin 17 (IL-17) family (IL-17A to IL-17F) 
and its distinct cytokine receptor family (IL-17Rs, including IL-17RA to IL-17RE) 
are important for normal host immune responses and the pathogenesis of 
human diseases, including airway inflammation and cancer [18, 19, 23, 38, 46]. 
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High IL-17 levels have been observed in multiple cancers, including colorectal 
cancer [22], hepatocellular carcinoma [41], breast cancer [4, 49], ovarian 
cancer [21], bladder cancer [37], prostate cancer [31], and lung cancer [5]. 
Furthermore, IL-17 promotes tumor development by inducing the suitable 
microenvironments at tumor sites by recruiting myeloid-derived suppressor 
cells [14]. Loss of IL-17 in mice is associated with reduced Stat3 signaling and 
reduced tumorigenesis [37].  
The interactions between IL-17 ligands and receptors are complicated. 
IL-17A and IL-17B are the ligands for IL-17RA and IL-17RB, respectively [32, 
45]. Furthermore, IL-17A binds to IL-17RA/IL-17RC with relatively higher 
affinity than IL-17F, and IL-17E (IL-25) may have a higher affinity for IL-17RB 
than IL-17B [23, 24, 39, 45]. IL-17R expression is up-regulated in the 
stimulated, inflamed tissues of patients with bowel diseases and various 
cancers [13, 32, 43], while IL-17E is secreted by non-malignant mammary 
epithelial cells and induces breast cancer apoptosis through IL-25R, an 
IL-17RB/IL-17RA heterodimer [9, 30]. In addition, high IL-17RB expression is 
correlated with a poor prognosis in patients with breast cancer [9, 16]. 
Accumulating evidence suggests that IL-17 plays important roles in cancer 
progression; however, the role of its receptor in lung cancer remains unclear.  
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In this study, we investigated whether IL-17 ligands and receptors regulated 
malignant phenotypes in lung cancer. We evaluated the relationship between 
IL-17 and patient survival by kaplan-merier plotter and also examined the 
expression levels of IL-17 receptors by cDNA microarray. According to the 
bioinformatical analysis, we identified the targets and then provided biological 
studies for verification. We focused on IL-17RB, the receptor responsible for 
the effects of IL-17B signaling on cancer progression, since a previous study 
showed that blocking IL-17RB inhibited the invasion and metastatic ability in 
cancer cells [40].  
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Materials and Methods 
Kaplan-Meier analysis of IL-17 family   
Kaplan-Meier analysis of overall survival was performed by using publicly 
available lung cancer microarray datasets (sample from 866 patients with 
adenocarcinoma and 675 patients with squamous cell carcinoma), stratified 
according to the expression of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and 
IL-17F. The publicly available online lung cancer microarray datasets were 
used for real-time validation of biomarkers related to patients survival 
(http://kmplot.com/analysis/index.php?p=service& cancer=lung) [12].  
 
Tissue sample collection 
Paired cancer tissue samples and adjacent non-cancerous lung tissue 
samples were collected from 139 newly diagnosed lung cancer patients who 
were surgically treated at Kaohsiung Medical University Hospital from 2007 to 
2013 (sample from 105 patients with adenocarcinoma and 34 patients with 
squamous cell carcinoma). This study was approved by the Institutional 
Review Board of Kaohsiung Medical University Hospital 
(KMUHIRB-E(II)-20170140), and written informed consent was obtained from 
each patient who participated in the study. Staging was performed according 
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to the American Joint Committee on Cancer (AJCC) tumor-node-metastasis 
(TNM) staging system [29]. Disease-free survival (DFS) was defined as the 
period between the date of surgery and the date of recurrence, and overall 
survival (OS) was defined as the period between the date of surgery and the 
date of the patient’s death from cancer.  
 
Immunohistochemistry  
Immunohistochemistry (IHC) was performed with a fully automated 
Bond-Max System (Leica Microsystems, Wetzlar, Germany). All staining steps 
were performed by the automated instrument, according to the manufacturer’s 
instructions (Leica Microsystems). The primary antibodies used for this 
experiment are shown in Supplementary Table 7. 
 
Evaluation of immunohistochemical staining 
IL-17RB expression was scored on a scale ranging from 0 to 4, according 
to the percentage of positively stained cells (0, negative; 1, ≤25% of cells 
stained positive; 2, 26–50% of cells stained positive; 3, 51–75% of cells 
stained positive; and 4, ≥76% of cells stained positive). The score for each 
specimen was determined by two independent experts simultaneously and 
10 
 
under the same conditions. Snail expression was scored on a scale ranging 
from 0-3, according to the percentage of positively stained cells (0, negative; 1, 
≤30% of cells stained positive; 2, 31–50% of cells stained positive; and 3, 
≥51% of cells stained positive). Similarly, Twist expression was scored on a 
scale ranging from 0-3, according to the percentage of positively stained cells 
(0, negative; 1, ≤50% of cells stained positive; 2, 51–75% of cells stained 
positive; and 3, ≥76 of cells stained positive). 
 
Cell lines and cell culture conditions 
The lung cancer cell lines CL1-0, CL1-5, H441, H460 and H520 were 
cultured in RPMI-1640 medium (containing 10% FBS and 1% PSG). The A549 
and H1299 cell lines were maintained in DMEM-F12 and DMEM with 10% FBS 
and 1% PSG, respectively.  
 
Reagents 
PD98059 (mitogen-activated protein kinase inhibitor, #P215) was 
purchased from Sigma (St. Louis, MO, USA). U-46619 (activator of ERK1 and 
ERK2, #sc-201242) was purchased from Santa Cruz Biotechnology (Dallas, 
TX, USA). The Proteome ProfilerTM Human Phospho-kinase Array Kit 
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(ARY003B) and recombinant human IL-17B (1248-IB-025/CF) were purchased 
from R&D Systems. 
 
Lentiviral infection  
The negative control lentiviral expression vector (LPP-NEG-Lv-105-025) 
and the lentiviral expression vector containing IL-17RB 
(LPP-Z1990-Lv105-200-S) were purchased from GeneCopoeiaTM. The 
pLKO-.1-shLuc967, shIL-17RB (TRC58814, TRC58816) and shIL-17B 
(TRC8595, TRC8596) lentiviral shRNA supernatants were purchased from 
National RNAi Core Facility (Taipei, Taiwan).  
 
Western blot analysis 
Total protein (50 μg) was extracted from the above cell lines and loaded 
onto a 10% SDS-PAGE gel. After electrophoresis, the proteins were 
transferred to a PVDF membrane, which was blocked with 5% noon-fat milk in 
TBST. Western blotting was performed using the appropriate antibodies 
(Supplementary Table 7). 
 
Growth curve assay 
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Cells (2000 cells/well) were seeded in a 96-well plate and incubated at 37°C 
with 5% CO2 for 24 to 72 h. The cell growth curve was determined by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
 
Cell migration and invasion assays 
Cell migration and invasion assays were performed with a FalconTM HTS 
Multiwell Insert System (8-µm pores, BD Biosciences, San Jose, CA). For 
invasion assay, the upper chamber of each multiwell insert (transwell) was 
precoated with Matrigel (BD Biosciences, San Jose, CA), and medium 
containing 10% FBS was added to each 24-well plate. The cells were then 
resuspended in serum-free medium (2x105/mL) and loaded into the upper 
chamber of the transwell in 100 μL aliquots. After 18-24 h, the cells that had 
migrated to the lower chamber were stained by crystal violet and counted 
under a light microscope (entire well). All experiments were performed in 
quadruplicate. The procedure for the migration assay was similar to that for the 
invasion assay; however, the upper chamber of the transwell was not coated 
with Matrigel for the migration assay. To block IL-17B, we incubated 
IL-17RB-overexpressing cells with an IL-17B-neutralizing antibody (4 μg/mL) 
for 48 h. Specifically, the cells were trypsinized for the transwell assay after 
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incubation, and an IL-17B-neutralizing antibody was added to the upper 
chamber of the transwell. 
 
Animal studies 
The animal experiments were conducted in accordance with a protocol 
approved by the Use Committee of Kaohsiung Medical University. 
Six-week-old male immunodeficient mice (BALB/cAnN.Cg-Foxn1nu/CrlNarl) 
were purchased from the National Laboratory Animal Center (NLAC, Taiwan). 
For in vivo metastasis assay, cells were resuspended in PBS (1x106 cells/100 
μL PBS/mouse) before being injected into each mouse via the tail vein. Five 
weeks after tail vein injection, all mice were sacrificed and the numbers of lung 
nodules were quantified by a dissecting microscope after the appropriate 
tissues were stained with hematoxylin and eosin (H&E). 
 
Enzyme-linked Immunosorbent Assay (ELISA) 
The cells were plated in 6-well plates and incubated at 37°C for 24 h, and 
then the medium was replaced with fresh medium, and the cells were 
incubated at 37°C for an additional 24 h. The conditioned medium was then 
collected, and IL-17B expression was determined by a human IL-17B duo-set 
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ELISA kit (DY1248, R&D Systems). 
 
Real time-PCR 
The stable cell lines CL1-0/vector control and CL1-0/IL-17RB (3x105 
cells/dish) were separately plated in 6-cm culture plates and incubated 
overnight at 37°C with 5% CO2. The CL1-0/IL-17RB cells were then treated 
with a MEK/ERK inhibitor for 24 h, followed by total RNA extraction for 
real-time PCR analysis (SYBR system). The following primers were used for 
this experiment: IL-17B, forward: 5’TCAACTTGCAGCTGTGGATGTC-3’ and 
reverse: 5’GGTCCTCCTGCATGGTGAAG-3’; and GAPDH, forward: 
5’GCACCACCAACTGCTTAGCA-3’ and reverse: 5’TCTTCTGGGTGGCA 
GTGATG-3’. 
 
Statistical analysis 
All statistical analyses were performed using SPSS (Statistical Package for 
the Social Sciences, version 19) software. Tissues with IL-17RB expression 
scores of 1 and 2 were categorized as having low IL-17RB expression, and 
tissues with scores of 3 and 4 were categorized as having high IL-17RB 
expression. Chi-square tests were performed to determine if differences in age 
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at diagnosis, sex, tumor grade, tumor size (T stage), the extent of lymph node 
metastasis (N stage), the extent of distant metastasis (M stage), patient 
performance and smoking status existed between the high IL-17RB 
expression group and the low IL-17RB expression group. Survival curves were 
generated by the Kaplan-Meier method, and the log rank test was used to 
evaulate the significance of differences between curves. Hazard ratios (HRs) 
and 95% confidence intervals (CIs) were calculated by univariate and 
multivariable Cox regression models, which were used to investigate the 
associations between clinicopathological characteristics and patient survival. 
P<0.05 was considered statistically significant. Spearman’s correlation test 
was performed to evaluate the significance of correlations between paramters. 
Difference between two groups was compared by Student t test. Multiple group 
settings were compared by Tukey’s post-hoc test. Other materials and 
methods provided in the online supplement. 
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Results 
In silico mRNA profiles of IL-17 and the IL-17R in lung cancer 
We evaluated the expression of the IL-17 family in lung cancer with online 
survival analysis software [12]. High IL17B, IL17C and IL17E expression was 
significantly associated with worse overall survival. However, IL17A, IL17D 
and IL17F expression was not significantly associated with worse overall 
survival (Fig. 1A). Cytokines act on target cells by binding to specific receptors. 
For example, IL-17B binds to IL-17RB, IL-17C binds to a heterodimer 
comprising IL-17RA/IL-17RE, and IL-17E binds to a heterodimer comprising 
IL-17RA/IL-17RB [34]. We subsequently examined the expression profiles of 
IL-17RA, IL-17RB and IL-17RE in other microarray datasets. Expression of 
IL-17RA, IL-17RB and IL-17RE in 20 normal lung tissues and the tissues from 
226 patients with lung adenocarcinoma (AdC) was compared in the GSE31210 
datasets. IL-17RB and IL-17RE expression levels were significantly 
up-regulated in patients with lung AdC compared with the normal lung tissue 
specimens (Fig. 1B). We also analyzed IL-17R expression in normal lung 
tissues and their paired tumor tissues from 5 patients with squamous cell 
carcinoma (SCC) in the GSE3268 datasets (Supplementary Fig. 1). IL-17RA 
expression was down-regulated in patients with lung AdC and SCC compared 
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with the normal lung tissue specimens. Notably, IL-17RA/IL-17RE 
heterodimers and IL-17RA/IL-17RB heterodimers are required to facilitate 
IL-17C- and IL-17E-mediated signaling, respectively [34]. These results 
suggested that IL-17B and IL-17RB may play an important role in lung cancer 
progression.  
 
IL-17RB up-regulation is associated with poor clinical outcomes in lung 
cancer 
To study the expression of IL-17RB protein in lung cancer patients, 40 sets 
of primary lung tumor specimens and paired pulmonary alveolar tissue 
specimens were analyzed by IHC. IL-17RB was significantly up-regulated in 
21 of the 40 lung tumor specimens compared with the pulmonary alveolar 
tissue specimens from the same patients (Fig. 2A; Supplementary Table 1 
and Table 2). To further evaluate IL-17RB protein in lung cancer, we 
examined its expression in primary lung tumors from 139 patients with lung 
cancer by IHC and correlated IL-17RB expression with the clinicopathological 
characteristics of these patients. As shown in Fig. 2B, IL-17RB protein 
expression in cancer tissues was classified into four quartiles (scores). 
Tissues with scores of 1 and 2 were categorized as having low IL-17RB 
18 
 
expression, and tissues with scores of 3 and 4 were categorized as having 
high IL-17RB expression. We found that high IL-17RB expression levels in 
lung cancer tissues were significantly associated with positive lymph nodes 
metastasis (N status; P=0.002) and positive distant metastasis (M status; 
P=0.03) (Table 1).  
Survival analysis by the log-rank test demonstrated the decreased 
disease-free survival (DFS) and overall survival (OS) rates in the high 
IL-17RB expression group compared with the low IL-17RB expression group 
(P<0.001)( Fig. 2C). We also evaluated the risk factors associated with lung 
cancer. Hazard ratios (HRs) were estimated by univariate and multivariable 
Cox regression (Fig. 2D; Supplementary Table 3 and Table 4). The univariate 
and multivariate analyses of DFS and OS showed that IL-17RB expression 
was a significant predictor of patient outcome (Fig. 2D; Supplementary Table 
3 and Table 4).  
 
Up-regulation of IL-17RB expression enhances lung cancer cell 
invasion/migration and metastasis  
From clinical data analysis, we found that IL-17RB may play an important 
role in lung cancer metastasis (Table 1). We then evaluated the effect of 
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IL-17RB on lung cancer cell invasion and migration. The western blotting 
results showed that the levels of endogenous IL-17RB were up-regulated in 
highly invasive CL1-5 and A549 cells, and IL-17RB was positively correlated 
with invasion ability in 6 human lung cancer cell lines (Fig. 3A-B). Knocking 
down IL-17RB expression in the highly invasive CL1-5 and A549 lung cancer 
cell lines significantly reduced invasion/migration ability in these cell lines 
compared with the shluc control cell line (Fig. 3C; Supplementary Fig. 2A). 
Conversely, overexpressing IL-17RB in the poorly invasive H441 and CL1-0 
cell lines significantly enhanced their invasion/migration ability compared with 
the control cell lines (Fig. 3D; Supplementary Fig. 2B). Neither knockdown nor 
overexpression of IL-17RB in lung cancer cells affected the proliferation 
potential of the cells (Supplementary Fig. 2C).  
We next investigated the effect of IL-17RB on metastasis in vivo. We 
stably overexpressed IL-17RB in H441 cells and intravenously injected the 
cells into the tail veins of mice. IL-17RB overexpression resulted in a 
significant increase in the number of metastatic nodules in the lungs of the 
indicated mice compared with vector control (Fig. 3E). We also quantified the 
degree of lymph node invasion by analyzing the expression of cytokeratin 18 
(CK18), a lymph node metastasis marker [42, 47]. IL-17RB overexpression 
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resulted in an increase of CK18 expression in mouse lymph nodes compared 
with vector control (Fig. 3F). 
 
IL-17RB promotes invasion/migration through activation of ERK 
signaling pathway 
To determine the molecular mechanisms by which IL-17RB regulates 
cancer cell invasion/migration, we used human phosphokinase arrays to 
examine control cells (H441/vector) and IL17RB-overexpressing H441 cells 
(Fig. 4A). The analysis showed that p-ERK1/2, p-GSK3β(Ser9), β-catenin, 
p-AMPK and p-Chk2 expression levels were increased in 
IL17RB-overexpressing H441 cells compared with control cells (Fig. 4A). We 
confirmed these results using western blotting, which showed that p-ERK1/2, 
p-GSK3β (Ser9), β-catenin and p-Chk2 expression levels were significantly 
increased in IL-17RB-overexpressing H441 cells compared with control cells 
(Fig. 4B). We focused on ERK1/2 in subsequent experiments because it 
phosphorylates the Ser9 residue of GSK3β, leading to β-catenin up-regulation 
[8]. We investigated whether IL-17RB promotes invasion/migration via ERK 
activation. Transwell assay demonstrated that blocking ERK1/2 
phosphorylation with an MEK/ERK inhibitor (PD98059) inhibited 
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invasion/migration in IL-17RB-overexpressing cells (Fig. 4C).  
We next investigated whether IL-17RB expression inactivates GSK3β and 
up-regulates β-catenin via the ERK1/2 pathway. As shown in Fig. 4D, 
IL-17RB-induced phosphorylation of ERK1/2 and GSK3β (Ser9) and 
expression of β-catenin were abolished by the MEK/ERK inhibitor PD98059. 
Similarly, IL-17RB knockdown resulted in reduced phosphorylation of ERK1/2 
and GSK3β (Ser9) and expression of β-catenin (Fig. 4E). These data 
suggested that IL-17RB enhanced lung cancer cell invasion through the 
ERK/GSKβ/β-catenin signaling pathway. 
 
IL-17RB up-regulation correlates with Snail/Twist expression in human 
lung cancer  
Activation of ERK pathway has been shown to be associated with 
epithelial-mesenchymal transition (EMT) [6, 26, 33]. We examined whether 
IL-17RB expression up-regulates EMT marker expression through the ERK1/2 
pathway. The results showed that the expression of Snail and Twist was 
significantly up-regulated in IL-17RB-overexpressing cells but was decreased 
in both MEK/ERK inhibitor-treated and IL-17RB-knockdown cells (Fig. 5A-B). 
We next examined whether IL-17RB expression was correlated with Snail and 
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Twist expression in lung cancer tissues. IHC staining for IL-17RB and Snail 
showed that IL-17RB expression was positively correlated with Snail 
expression in lung cancer tissues (Spearman nonparametric correlation test; 
correlation coefficient=0.247; P=0.014; n=79) (Fig. 5C and 5E; Supplementary 
Table 5). Similar result was observed between IL-17RB and Twist, as IL-17RB 
expression was positively correlated with Twist expression in lung cancer 
tissues (Spearman nonparametric correlation test; correlation 
coefficient=0.234; P=0.007; n=109) (Fig. 5D and 5F; Supplementary Table 6). 
Moreover, we analyzed the GSE3141 datasets, which contained data for 111 
patients with lung cancer, and obtained results similar to our study (Fig. 5G).  
 
IL-17RB up-regulation mediated IL-17B secretion through the ERK 
pathway 
In our study, the MEK/ERK inhibitor PD98059 decreased IL-17RB 
expression in IL-17RB-overexpressing cells (Fig. 4D and 5A). Furthermore, it 
has been reported that IL-17RB expression is induced by IL-17B in other cell 
types [1, 16].  We therefore explored the possibility that IL-17B induces 
IL-17RB expression in lung cancer cells. IL-17B treatment caused significant 
IL-17RB up-regulation in CL1-0 and H441 lung cancer cells (Fig. 6A). Also, 
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IL-17RB overexpression resulted in the up-regulation of IL-17B expression 
levels, whereas treatment with the MEK/ERK inhibitor PD98059 
down-regulated IL-17B levels in IL-17RB-overexpressing cells (Fig. 6B; 
Supplementary Fig 3). These results indicated that IL-17RB-ERK signaling 
may be involved in IL-17B synthesis. 
We also investigated whether IL-17B mediated invasion/migration in 
IL-17RB-overexpressing cells. IL-17RB overexpression-induced migration and 
invasion activity was suppressed by an IL-17B-neutralizing antibody (Fig. 6C). 
In addition, IL-17B knockdown resulted in IL-17RB and ERK pathway 
down-regulation in IL-17RB-overexpressing CL1-0 cells (Fig. 6D). Conversely, 
treatment with the ERK activator U46619 caused a significant increase in ERK 
phosphorylation in CL1-0 cells, leading to IL-17B and IL-17RB up-regulation, 
whereas treatment with the MEK inhibitor caused a decrease in ERK 
phosphorylation in CL-1-0 cells (Fig. 6E). We subsequently evaluated IL-17B 
levels in the serum of mice with lung metastasis of IL-17RB-overexpressing 
cancer cells and found that IL-17B levels were significantly higher in these 
mice than in vector control-treated mice (Fig. 6F). Furthermore, correlation 
analysis of IL-17B and IL-17RB, which was performed using GSE3141 
datasets (lung cancer microarray datasets), showed that IL-17B expression 
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was positively correlated with IL-17RB expression (Fig. 6G). Taken together, 
our results suggest that IL-17RB activation is required for IL-17B-mediated 
ERK phosphorylation, which leads to up-regulation of β-catenin, Snail and 
Twist and contributes to lung cancer metastasis (Fig. 6H). 
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Discussion 
In this study, the IL-17 family was assessed in lung cancer patients, with 
high IL-17B and its receptor IL-17RB identified as poor prognostic factors. 
IL-17B and IL-17RB were associated with poor survival in patients with lung 
cancer, with high IL-17RB expression associated with shorter DFS and OS 
times, indicating that they play an important role in lung cancer progression. 
Although other members of the IL-17 family have been implicated in tumor 
metastasis, such as IL-17A mediated endothelial breach promoting lung 
metastasis [20], we have demonstrated that these ligands are not associated 
with a poorer prognosis and are not significantly expressed in lung cancer 
tissues.   
IL-17RB overexpression increased migration/invasion activity in 
noninvasive lung cancer cell lines, whereas IL-17RB knockdown inhibited 
migration/invasion ability in highly invasive cell lines. Our data demonstrated 
that increases in IL-17RB-mediated phosphorylation of ERK led to 
phosphorylation of GSK3β, which induced the up-regulation of β-catenin, a 
transcription factor in the Wnt pathway [25]. Moreover, the IL-17RB-ERK 
pathway mediated IL-17B up-regulation in lung cancer cell lines, whereas 
treatment with IL-17B increased the effects of IL-17RB expression via the ERK 
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pathway in lung cancer cells. These findings suggest that IL-17B-IL-17RB 
signaling and ERK participate in a positive feedback loop to promote lung 
cancer metastasis (Fig. 6H).  
Furthermore, we showed that IL-17RB overexpression promoted 
invasion/migration activity and increased IL-17B synthesis via the ERK 
pathway in lung cancer cells. The invasion/migration assay showed that 
IL-17B blockade inhibited invasion/migration ability in IL-17RB-overexpressing 
cells (Fig. 6C). Knocking down IL-17B significantly reduced IL-17RB 
expression and ERK phosphorylation in IL-17RB-overexpressing cells 
compared with IL-17RB-overexpressing shluc cells (Fig. 6D). Moreover, 
treatment with IL-17B induced IL-17RB up-regulation in CL1-0 and H441 lung 
cancer cells, whereas knockdown of IL-17B inhibited IL-17RB expression in 
IL-17RB-overexpressing cells (Fig. 6A and 6D). Based on these findings, we 
surmised that IL-17RB is required for IL-17B activation, which results in 
enhanced invasion/migration in lung cancer cells.  
Other mechanistic pathways have been suggested for IL-17, including 
IL-17B/IL-17RB pro-survival effects in breast cancer cells via TRAF6, NF-kB 
and BCL-2 mediated anti-apoptosis [16]. IL-17 has also been shown to 
promote invasion and metastasis via MMP7 induced EMT in prostate cancer 
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[48]. One study relevant to lung cancer suggests that IL-17 may promotes lung 
cancer cell migration/invasion activity by inducing EMT and up-regulating the 
NF-kB/ZEB1 pathway, but this study fails to distinguish between IL-17 
subtypes, and the effects may stem from the less clinically relevant IL-17A 
form [11]. In agreement with our result (Fig. 1A), Jungnickel et al. also showed 
that the expression of IL-17C correlates with poor disease outcome in lung 
cancer, but they did not investigative the role of its receptor in lung cancer [17]. 
In contrast, our data using the clinically relevant IL-17B subtype demonstrated 
that EMT in lung cancer may be mediated via Snail and Twist, as IL-17RB 
overexpression resulted in their up-regulation, whereas IL-17RB knockdown 
inhibited their expression in lung cancer cell lines.  
An early study reported that T-helper type 17 (Th17) cells, a CD4+ T cell 
subset, generated IL-17 in response to the cytokines IL-6, TGF-β, IL-21, IL-1, 
and IL-23 in autoimmune diseases [36]. Targeting ERK/MAPK signaling with a 
MEK inhibitor effectively reduces IL-17 synthesis in Th17 cells, whereas 
treatment with IL-23 and IL-1β increases IL-17 levels in Th17 cells [3, 36]. 
Furthermore, treatment with the ERK activator U49919 significantly 
up-regulated IL-1β and IL-6 in the microglia cell line BV2 [44]. Here, we 
showed that U49916 treatment increased IL-17B and IL-17RB expression in 
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CL1-0 lung cancer cells (Fig. 6E). Moreover, ERK phosphorylation induces 
IL-17B synthesis in lung cancer cells, a change inhibited by the MEK inhibitor 
(Fig. 6E). Recent studies also showed that IL-17B treatment or IL-17RB 
overexpression led to ERK phosphorylation and promoted metastasis whereas 
treatment with a neutralizing antibody against IL-17RB inhibits metastasis in 
pancreatic cancer [40]. We could not exclude the possibility that IL-17B is 
secreted by other cell types; however, this is the first study to demonstrate that 
IL-17RB mediated IL-17B synthesis via the ERK pathway, providing the basis 
for a therapeutic target that may reduce lung cancer cell metastasis.  
In conclusion, this is the first study to identify clinically relevant subtypes 
of the IL-17 family through analysis of lung cancer patient tissues – IL-17B and 
IL-17RB - and delineate their mechanism of action in lung cancer invasion and 
metastasis. As clear evidence emerges of the role that inflammation plays in 
cancer progression, IL-17B-IL-17RB has been identified as both a key 
prognostic marker and ideal target for lung cancer treatment.  
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Figure Legends 
Fig1. Identification of IL-17RB as a potential target for the prevention of 
lung cancer progression. (A) Kaplan-Meier analysis of OS, according to the 
expression of IL17A, IL17B, IL17C, IL17D, IL17E and IL17F, using publicly 
available lung cancer online microarray datasets software. HR=hazard ratio. 
(B) Relative IL17RA (228685_at, 220101_at and 229295_at), IL17RB 
(219255_x_at and 224156_x_at) and IL17RE (236186_x_at) mRNA levels in 
patients with lung cancer adenocarcinoma in the GSE31210 datasets. The 
significance is determined by Student t test. **, P<0.01. 
 
Fig2. IL-17RB is overexpressed in lung cancer and is correlated with 
poor survival. (A) Quantification of IL-17RB expression in 40 paired lung 
cancer specimens and significance determined by Student t test. *, P<0.05. (B) 
IL-17RB expression in lung cancer tissues. (C) Kaplan-Meier survival curves 
for disease-free survival (DFS) and overall survival (OS) in lung cancer 
patients according to IL-17RB expression, as determined by IHC. (D) HRs for 
the risk of death, as determined by multivariable Cox regression, in lung 
cancer patients. 
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Fig3. IL-17RB enhances migration/invasion and metastasis in lung 
cancer. (A) Top, Western blot analysis of IL-17RB expression in lung cancer 
cell lines. Bottom, invasive abilities of lung cancer cell lines. (B) Correlation 
between IL-17RB expression and invasion ability in lung cancer cell lines. (C) 
IL-17RB knockdown on migration/invasion potential of A549 and CL1-5 lung 
cancer cells. Top, Western blot analysis of IL-17RB expression in 
IL-17RB-knockdown cells vs. shluc control cells. Bottom, A549 and CL1-5 
migration and invasion ability after IL-17RB knockdown. The data are 
presented as the mean ± SD and the significance is determined by one way 
ANOVA followed by Tukey’s post hoc test. *, P<0.05; **, P<0.01. (D) IL-17RB 
overexpression on migration/invasion potential of CL1-0 and H441 lung cancer 
cells. Top, Western blot analysis of IL-17RB expression after IL-17RB 
overexpression vs. vector control treatment. Bottom, CL1-0 and H441 
migration and invasion ability after IL-17RB overexpression. The data are 
presented as the mean ± SD and the significance is determined by Student t 
test. **, P<0.01. (E) Representative image of H&E-stained lung tissues from 
mice intravenously injected with H441-vector or H441-IL17RB (n=6). The data 
are presented as the mean ± SD and the significance is determined by Student 
t test. **, P<0.01. (F) Representative images of CK18 expression in the lymph 
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nodes of vector control mice and IL-17RB-overexpressing mice. The data are 
presented as the mean ± SD and the significance is determined by Student t 
test. **, P<0.01. 
 
Fig4. IL-17RB promotes invasion/migration through the ERK/β-catenin 
pathway. (A) Top, phosphorylation kinase array assay in 
IL-17RB-overexpressing H441 cells. Bottom, phosphorylation levels of 
candidate proteins relative to the control. (B) Western blot analysis of 
candidate kinases in IL-17RB-overexpressing H441 cells. (C) Migration and 
invasion ability in CL1-0/IL-17RB and H441/IL-17RB cells after treatment with 
the MEK/ERK inhibitor PD98059 (25 μM). The data are presented as the mean 
± SD and the significance is determined by one way ANOVA followed by 
Tukey’s post hoc test. *, P<0.05; **, P<0.01. (D) Western blot analysis of 
IL-17RB, ERK, GSK3β and β-catenin expression in CL1-0/IL-17RB and 
H441/IL-17RB cells after treatment with the MEK/ERK inhibitor PD98059 (25 
μM). (E) Comparison of IL-17RB, ERK, GSK3β and β-catenin expression 
between IL-17RB-knockdown A549 and CL1-5 cells and shluc control cells. 
 
Fig5. IL-17RB expression is correlated with Snail/Twist expression in 
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lung cancer tissues. (A) Western blot analysis of IL-17RB and EMT markers 
in CL1-0/IL-17RB and H441/IL-17RB cells after treatment with the MEK/ERK 
inhibitor. (B) The expression of EMT markers in A549 and CL1-5 lung cancer 
cells after IL-17RB knockdown. (C) Representative images of IL-17RB and 
Snail IHC staining in lung cancer tissues. (D) Representative images of IHC 
analysis for IL-17RB and Twist in lung cancer tissues. (E and F) Quantification 
of IL-17RB and Snail (E)/Twist (F) expression by IHC analysis of lung cancer 
tissues. The number (n) of specimens is shown at the top of each column. *, 
P<0.05. (G) Analysis of the correlation between IL-17RB expression and 
Snail/Twist mRNA expression using GSE3141 datasets. 
 
Fig6. IL-17RB enhanced lung cancer migration/invasion in a 
IL-17B-mediated manner. (A) Top, Western blot analysis of IL-17RB 
expression following treatment with IL-17B (12.5 ng/mL). Bottom, relative 
expression of IL-17RB in IL-17B treated cells relative to untreated cells and the 
significance is determined by Student t test. *, P<0.05. (B) IL-17B levels in 
IL-17RB-overexpressing cells after treatment with the MEK/ERK inhibitor 
PD98059. IL-17B concentrations in conditioned medium were quantified by 
ELISA. The data are shown as the mean ± SD and the significance is 
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determined by one way ANOVA followed by Tukey’s post hoc test. *, P <0.05. 
(C) Migration/invasion ability in CL1-0/IL-17RB cells and H441/IL-17RB cells 
after pretreatment with an IL-17B-neutralizing antibody (4 μg/mL) or control 
IgG (4 μg/mL) for 48 hours. The data are shown as the mean ± SD and the 
significance is determined by one way ANOVA followed by Tukey’s post hoc 
test. *, P<0.05, **, P <0.01. (D) IL-17B levels in IL-17RB-overexpressing CL1-0 
cells after IL-17B knockdown. Left, IL-17B levels were measured by ELISA. 
The data are shown as the mean ± SD and the significance is determined by 
one way ANOVA followed by Tukey’s post hoc test. **, P<0.01. Right, Western 
blot analysis of IL-17RB, p-ERK1/2 and ERK expression following IL-17B 
knockdown. (E) Western blot analysis of p-ERK1/2, ERK, IL-17B and IL-17RB 
expression following treatment with the ERK activator U46619 (10 μM) or the 
MEK inhibitor PD98059 (25 μM). (F) IL17B levels, determined by ELISA, in the 
serum of mice with lung metastasis of IL-17RB-overexpressing cancer cells 
and vector control-treated mice (n=5). The data are shown as the mean ± SD 
and the significance is determined by Student t test. **, P<0.01. (G) IL-17B and 
IL-17RB mRNA expression correlation analysis was performed using 
GSE3141 datasets. (H) Model showing that IL-17B-IL-17RB signaling induced 
ERK phosphorylation, leading to up-regulation of β-catenin, Snail, Twist, and 
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cell invasion and metastasis in lung cancer. 
Figure1 Identification of IL-17RB
Figure2_IL-17RB is overexpressed IHC
Figure3_3.IL-17RB enhances migration
Figure4_ERK/ß-catenin
Figure5_Snail/Twist expression
Figure6_IL-17B-IL-17RB
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Table 1. Association between IL-17RB expression and 
clinicopathological characteristics in lung cancer. 
   IL17-RB  
   Low (1,2)  High (3,4)  
Variables Item Patient No. No.  No. p value* 
  139 92  47  
Age (y) ≤70  93 61  32 0.833 
 >70  46 31  15  
Sex Female  47 34  13 0.273 
 Male  92 58  34  
Grade I  26 20  6 0.093 
 II  99 66  33  
 III  14 6  8  
T status T1/T2 113 74  39 0.716 
 T3/T4  26 18  8  
N status Negative (N0)  84 64  20 0.002* 
 Positive 
(N1/N2/N3)  55 28 
 
27  
M status Negative 119 83  36 0.030* 
 Positive  20 9  11  
Performance 0 105 73  32 0.144 
 1  34 19  15  
Smoking status Never  85 62  23 0.094 
 Former  25 13  12  
 Current  29 17  12  
*P values <0.05 were considered statistically significant (chi-square test for categorical 
variables).   
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